The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback